DNA trinucleotide repeat expansions are known to be associated with several hereditary neurodegenerative disorders, including Huntington disease, Fragile X syndrome and spinocerebellar ataxia.

A recent theory about the basis for fragile X syndrome is now validated in a mouse model. The findings point the way to treatment options targeting group 1 metabotropic glutamate receptors.

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

is concerned about the lack of awareness around Fragile X syndrome and about how common it is. “There is a surprising lack of awareness around Fragile X syndrome,” says Pete Richardson ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.